Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses
Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses
复制标题
DOI：
10.1111/j.1469-0691.2012.03820.x
复制
发表时间：
2012-07-01
影响因子：
14.2
通讯作者：
Fang, C-T.
中科院分区：
文献类型：
--
作者：
Chiang, T-Y;Lin, W-C.;Fang, C-T.
临床微生物感染2012; 18：E232 E234摘要台湾疾病预防控制中心调查了2003 - 2010年期间四例复发性输入性间日疟病例。分子基因分型结果和缺乏发病间旅行史表明，其中两名分别在印度尼西亚和所罗门群岛感染间日疟的患者，尽管在首次发病时完成了标准剂量伯氨喹治疗（30 mg/天，持续14天），但在间隔34个月后复发。用更高剂量的伯氨喹治疗（60毫克/天，持续14天）防止了这两名患者的进一步复发。这一发现要求进一步监测伯氨喹治疗东南亚和大洋洲获得的间日疟原虫的疗效。
Clin Microbiol Infect 2012; 18: E232E234 Abstract Taiwan CDC investigated four cases of recurrent imported vivax malaria during 20032010. Molecular genotyping results and the lack of inter-episodes travel history indicated that two of the patients, who acquired vivax malaria in Indonesia and the Solomon Islands, respectively, suffered relapses after an interval of 34 months, despite completing standard-dose primaquine therapy (30 mg/day for 14 days) for the first episode. Treatment with a higher dose of primaquine (60 mg/day for 14 days) prevented further relapse in both patients. This finding calls for further monitoring of the therapeutic efficacy of primaquine in treating Plasmodium vivax acquired in southeast Asia and Oceania.